Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-103 in Participants Ages 12-35 With Recent Onset Stage 3 Type 1 Diabetes

NCT06783309 is registered in ClinicalTrials.gov with COUR Pharmaceutical Development Company, Inc. as lead sponsor.

NCT NCT06783309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06783309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-103 in Participants Ages 12-35 With Recent Onset Stage 3 Type 1 Diabetes
Lead sponsor
COUR Pharmaceutical Development Company, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 12, 2025
Completion date
June 30, 2027
Enrollment
72 (estimated)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

t1d, t1dm, t1dm - type 1 diabetes mellitus, type 1 diabetes, type 1 diabetes (juvenile onset), type 1 diabetes in adolescence, type 1 diabetes in children, type 1 diabetes mellitis, type 1 diabetes mellitus, type 1 diabetes patients